In this series, we explore the impact of data from the National Genomic Research Library and highlight opportunities for ...
In a safety review, the FDA identified 14 cases of seizures linked to vitamin B6 deficiency in patients taking ...
Future treatment resistance to focal epilepsy therapy was significantly more likely in individuals who reported suicidal ...
This morning on “The Rhode Show” we welcomed Dr. Preeti Gupta, a board-certified neurologist specializing in epilepsy, and the Founder of the NeuroLogic Center for Seizures + Epilepsy.
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase ...
Despite trying antidepressants and CBT, the “panic” episodes only worsened, especially in the three years before the test.
Sheffield Children’s NHS Foundation Trust has become the first site in Europe to recruit a patient to a major international clinical trial investigating a potential new treatment for a severe form of ...
Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...
According to WHO, non-communicable diseases (NCDs) kill 41 million people each year, of which 17 million people die before age 70. Cardiovascular disease accounts for most NCD deaths, followed by ...
Rapport Therapeutics, Inc. ( RAPP) Stifel 2026 Virtual CNS Forum March 17, 2026 9:30 AM EDT Great. Good morning, everybody. Happy to be here, moderating this panel with Abe Ceesay, CEO of Rapport ...
Health Secretary Robert F. Kennedy Jr. recently said that the diet could “cure” schizophrenia. We asked experts about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results